A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

BACKGROUND: Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomized double-blind clinical trial, utilized a Bayesian design with response-adaptiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Swanson, Chad J., Zhang, Yong, Dhadda, Shobha, Wang, Jinping, Kaplow, June, Lai, Robert Y. K., Lannfelt, Lars, Bradley, Heather, Rabe, Martin, Koyama, Akihiko, Reyderman, Larisa, Berry, Donald A., Berry, Scott, Gordon, Robert, Kramer, Lynn D., Cummings, Jeffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053280/
https://www.ncbi.nlm.nih.gov/pubmed/33865446
http://dx.doi.org/10.1186/s13195-021-00813-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053280/
https://www.ncbi.nlm.nih.gov/pubmed/33865446
http://dx.doi.org/10.1186/s13195-021-00813-8

Ejemplares similares